Overview

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of cabozantinib, at different doses, in combination with cetuximab to find out what effects, if any, this combined treatment has on people with HNSCC.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Cetuximab